Streetbeat News

Analyst Ratings

DIS

KeyBanc Capital Markets analyst Brandon Nispel has downgraded Walt Disney Co. (NYSE:DIS) from Overweight to Sector Weight, citing five reasons. These include high expectations for Disney's domestic Parks, doubts about attendance and per-cap spending trends, potential margin pressure due to Disney's new labor contract in Florida and the accelerated depreciation of the Starcruiser, stalled direct-to-consumer subscriber growth, and structural changes in content. Disney shares were down 0.79% in premarket trading.

Portfolio Pulse from Shanthi Rexaline

June 29, 2023 | 10:37 am

KRO

METC

SBSW

Three high-yielding dividend stocks in the materials sector have been highlighted by Wall Street's most accurate analysts. These include Kronos Worldwide, Inc. (KRO), Sibanye Stillwater Limited (SBSW), and Ramaco Resources, Inc. (METC). Recent analyst ratings and price targets for these stocks have been provided, along with recent news such as quarterly results and operating updates.

Portfolio Pulse from Lisa Levin

June 29, 2023 | 10:37 am

AVXL

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Anavex Life Sciences (NASDAQ:AVXL) and maintained a $54 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:15 am

NKE

Nike Inc. (NYSE:NKE) is expected to report lower Q4 earnings at 67 cents per share, down from 90 cents per share a year ago. The company's revenue is projected to be $12.59 billion. Several analysts have recently adjusted their price targets for Nike, with most maintaining an Overweight or Outperform rating, but one analyst downgraded the stock from Hold to Sell.

Portfolio Pulse from Lisa Levin

June 29, 2023 | 10:15 am

FWBI

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on First Wave BioPharma (NASDAQ:FWBI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:14 am

CARM

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:13 am

ROIV

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $15 to $18.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:13 am

TIL

HC Wainwright & Co. analyst Mitchell Kapoor has initiated coverage on Instil Bio (NASDAQ:TIL) with a Buy rating and a price target of $2.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:11 am

AREC

HC Wainwright & Co. analyst Heiko Ihle has reiterated a 'Buy' rating on American Res (NASDAQ:AREC) and maintained a price target of $3.5.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:09 am

TBLA

Needham analyst Laura Martin has reiterated a Buy rating on Taboola.com (NASDAQ:TBLA) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:08 am